RxDoctor Payments Data

Kimberly Lucey, MD

Ophthalmology · Enfield, CTNPI 1134130867

Payments from drug & device makers

$653in general payments, 2019–2025

Across 35 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$100
  • Bausch & Lomb Americas Inc.$93
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$88
  • AbbVie$74
  • Kala Pharmaceuticals, Inc.$55
  • Novartis$53
  • plus $190 from 7 others

What the payments were for

  • Food & beverage$653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$653 in reported general payments places this provider in the 45th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$130,176
Medicare patients
373
Services billed
2,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost182$114,336
RestasisCyclosporine24$33,851
RocklatanNetarsudil Mesylat/Latanoprost52$31,716
TyrvayaVarenicline Tartrate31$25,273
CombiganBrimonidine Tartrate/Timolol26$11,907
Lotemax SmLoteprednol Etabonate45$11,391
Travatan ZTravoprost21$10,551
Cyclosporine15$10,005
ProlensaBromfenac Sodium15$5,984
Timolol Maleate67$4,131
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat141$2,814
Latanoprost213$2,162
MoxifloxacinMoxifloxacin Hcl26$677
Prednisolone Acetate25$638
ValacyclovirValacyclovir Hcl13$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$74$160,094232 claims
Oyster Point Pharma, Inc.Tyrvaya$39$25,27331 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa$88$17,37560 claims
NovartisTravatan Z$53$10,55121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →